Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,178,539 papers from all fields of science
Search
Sign In
Create Free Account
moxifloxacin
Known as:
1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
, MOXI
Expand
A fluoroquinolone antibiotic with antibacterial activity. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
39 relations
Amiodarone
Amiodarone hydrochloride
Avelox 400 mg oral tablet includes Avelox ABC Pack
Bacterial Infections
Expand
Broader (3)
Anti-Bacterial Agents
Fluoroquinolones
Topoisomerase II Inhibitors
Narrower (5)
Avelox
Moxifloxacin hydrochloride
Octegra
Proflox
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Dawei Wang
,
Bo Hu
,
+11 authors
Z. Peng
JAMA
2020
Corpus ID: 211050495
Importance In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of…
Expand
Highly Cited
2014
Highly Cited
2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
S. Gillespie
,
A. Crook
,
+6 authors
A. Nunn
New England Journal of Medicine
2014
Corpus ID: 2476661
BACKGROUND Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month…
Expand
Highly Cited
2014
Highly Cited
2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
A. Jindani
,
T. Harrison
,
+20 authors
D. Mitchison
New England Journal of Medicine
2014
Corpus ID: 14312398
BACKGROUND Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. METHODS We…
Expand
Highly Cited
2011
Highly Cited
2011
BDDCS Applied to Over 900 Drugs
L. Benet
,
F. Broccatelli
,
T. Oprea
AAPS Journal
2011
Corpus ID: 10596533
Here, we compile the Biopharmaceutics Drug Disposition Classification System (BDDCS) classification for 927 drugs, which include…
Expand
Highly Cited
2009
Highly Cited
2009
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
S. Dorman
,
John L. Johnson
,
+16 authors
R. Chaisson
American Journal of Respiratory and Critical Care…
2009
Corpus ID: 19217345
RATIONALE Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis…
Expand
Review
2007
Review
2007
Bacteroides: the Good, the Bad, and the Nitty-Gritty
H. Wexler
Clinical Microbiology Reviews
2007
Corpus ID: 30170463
SUMMARY Summary: Bacteroides species are significant clinical pathogens and are found in most anaerobic infections, with an…
Expand
Highly Cited
2006
Highly Cited
2006
Inhibitors of NF-κB signaling: 785 and counting
T. Gilmore
,
M. Herscovitch
Oncogene
2006
Corpus ID: 6579201
Nuclear factor kappa B (NF-κB) transcription factors regulate several important physiological processes, including inflammation…
Expand
Highly Cited
2005
Highly Cited
2005
An epidemic, toxin gene-variant strain of Clostridium difficile.
L. McDonald
,
G. Killgore
,
+5 authors
D. Gerding
New England Journal of Medicine
2005
Corpus ID: 43628397
BACKGROUND Recent reports suggest that the rate and severity of Clostridium difficile-associated disease in the United States are…
Expand
Highly Cited
2004
Highly Cited
2004
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
E. Nuermberger
,
T. Yoshimatsu
,
+5 authors
J. Grosset
American Journal of Respiratory and Critical Care…
2004
Corpus ID: 35875593
Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control…
Expand
Highly Cited
2004
Highly Cited
2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
T. Gumbo
,
A. Louie
,
M. Deziel
,
L. Parsons
,
M. Salfinger
,
G. Drusano
Journal of Infectious Diseases
2004
Corpus ID: 12339712
BACKGROUND Moxifloxacin is a quinolone antimicrobial that has potent activity against Mycobacterium tuberculosis. To optimize…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE